Cargando…
FGL1 as a Novel Mediator and Biomarker of Malignant Progression in Clear Cell Renal Cell Carcinoma
Clear cell renal cell carcinoma (ccRCC), which is the most prevalent renal cell carcinoma subtype, has a poor prognosis. Emerging strategies for enhancing the immune response in ccRCC therapy are currently being investigated. Fibrinogen-like Protein 1(FGL1) is a novel mechanism that tumors may use t...
Autores principales: | Lv, Zheng, Cui, Bo, Huang, Xing, Feng, Hua-Yi, Wang, Tao, Wang, Han-Feng, Xuan, Yun-Dong, Li, Hong-Zhao, Ma, Xin, Huang, Yan, Zhang, Xu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695555/ https://www.ncbi.nlm.nih.gov/pubmed/34956878 http://dx.doi.org/10.3389/fonc.2021.756843 |
Ejemplares similares
-
Targeting FGL2 in glioma immunosuppression and malignant progression
por: Ma, Xiaoyu, et al.
Publicado: (2022) -
Effect of m(6)A RNA Methylation Regulators on Malignant Progression and Prognosis in Renal Clear Cell Carcinoma
por: Wang, Jiawu, et al.
Publicado: (2020) -
Immune Checkpoint FGL1 Expression of Circulating Tumor Cells Is Associated With Poor Survival in Curatively Resected Hepatocellular Carcinoma
por: Yan, Qing, et al.
Publicado: (2022) -
Identification of CXCL10 as a Prognostic Biomarker for Clear Cell Renal Cell Carcinoma
por: Qu, Genyi, et al.
Publicado: (2022) -
Apolipoprotein C1 (APOC1): A Novel Diagnostic and Prognostic Biomarker for Clear Cell Renal Cell Carcinoma
por: Cui, Yankang, et al.
Publicado: (2020)